CRO WorldCare Clinical (WCC) has launched a service that enables simultaneous capture and analysis of both standard tumor assessments, including Response Evaluation Criteria in Solid Tumors (RECIST) and the immune-related response criteria (irRC). WCC’s method has been validated and is being used to evaluate new immune-related treatments.  

WCC developed its combination case report form (CRF) to facilitate concurrent tumor assessments using both methods. The service was designed for sponsors developing immunotherapeutic agents that want to analyze performance using irRC, but also want to capture RECIST responses until the newer irRC becomes more established.

“Employing a combined approach to tumor assessment allows for time savings when performing the imaging interpretation, resulting in a significant cost savings to the sponsor,” said Richard Walovitch, Ph.D., president of WCC. “Using our combination CRF, we’re able to programmatically calculate the response using the criteria of both methods.”